Autopsy report · NCT04294784

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer

“slow recruitment forcing early suspension of screening and enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 3 years 8 months before it stopped.
• 58 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Huazhong University of Science and Technology

Sponsor type

University, hospital or other

Conditions

Gastric Cancer; GastroEsophageal Cancer

Interventions

Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor); Albumin-bound Paclitaxel

Participants

58

Sites

1

Countries

China

Trials that died the same way

• Iloprost for Bridging to Heart Transplantation in PH
  “Delay in recruitment” (74% match in meaning)
• Ultrasound and Endometrial Hyperplasia
  “enrollment of participants has halted prematurely; difficulty with recruitment” (73% match in meaning)
• Serum-derived Bovine Immunoglobulin Effect on Mucositis
  “Recruitment slower than anticipated” (69% match in meaning)
• IU Health Krannert Personalized Medicine Study
  “Slower than anticipated recruitment” (69% match in meaning)
• A Study of the PedSCath Pediatric Sampling Catheter Versus Current Standard of Care.
  “Slow Enrollment, Recruiting Difficulties” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.